Cord Blood CAR-NK Cells: Favorable Initial Efficacy and Toxicity but Durability of Clinical Responses Not Yet Clear
- PMID: 32289266
- DOI: 10.1016/j.ccell.2020.03.018
Cord Blood CAR-NK Cells: Favorable Initial Efficacy and Toxicity but Durability of Clinical Responses Not Yet Clear
Abstract
Chimeric antigen receptor (CAR)-T cell immunotherapy is highly effective against B lineage cancers but at the expense of potentially serious toxicity such as cytokine release syndrome (CRS) and neurotoxicity. Recent work provided clinical evidence that allogeneic, cord blood CAR-NK cells induce high rates of non-durable clinical responses without CRS or neurotoxicity.
Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Interests AK is a scientific advisor for AgenTus, a member of the scientific research panel of Gilead Greece, and has filed a patent for transduction and expansion of iNKT cells.
Comment on
-
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607. N Engl J Med. 2020. PMID: 32023374 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources